Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1022820230140010024
Journal of Multiple Sclerosis and Neuroimmunology
2023 Volume.14 No. 1 p.24 ~ p.33
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review
Kwon Young-Nam

Kim Sung-Min
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system that is distinct from multiple sclerosis and neuromyelitis optica spectrum disorder. While an international consensus has recently been established regarding the clinical features and diagnostic criteria of MOGAD, further studies are needed to improve our understanding of the disease, including its treatment and prognosis. Accurate diagnostic methods and a comprehensive understanding of the clinical features are crucial, as test results must be integrated with clinical considerations. Currently, there is a lack of randomized controlled clinical trials on the treatment of MOGAD, but observational studies suggest that immunotherapy may be effective. This review aims to provide a comprehensive overview of the pathophysiology, clinical features, and recently established diagnostic criteria of MOGAD, as well as available treatment options, and prognosis.
KEYWORD
Myelin-oligodendrocyte glycoprotein, Demyelinating diseases, Autoimmune disease, Diagnosis, Therapeutics
FullTexts / Linksout information
Listed journal information